ArticleThe American journal of case reports2025
Solitary Plasmacytoma of the Rib: A Report of a Rare Case.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Solitary plasmacytoma of bone (SPB) is a rare malignant plasma cell neoplasm, comprising 6% of all plasma cell tumors. It is characterized by a solitary osteolytic lesion. CASE REPORT This report describes an asymptomatic SPB in the rib of a 66-year-old man. X-ray and computed tomography (CT) initially showed localized bone resorption and destruction of the right fifth posterior rib, with a 4.0×2.4×2.8 cm soft-tissue mass. Single-photon emission computed tomography (SPECT) confirmed isolated rib involvement without multifocal skeletal lesions. Pathology and immunohistochemistry (CD138+, CD38+) confirmed the SPB diagnosis. SPB usually presents as a single osteolytic lesion, which often occurs in the vertebrae and skull. Rib involvement in SPB is uncommon, due to its nonspecific imaging features, often causing diagnostic delays or misdiagnosis. Radiotherapy is the primary treatment for localized SPB. However, there is a 30% to 50% risk of progression to multiple myeloma (MM), necessitating long-term surveillance of serum M protein and periodic imaging. CONCLUSIONS This case emphasizes that for adult patients with isolated rib destruction with or without the formation of soft-tissue masses, the possibility of SPB should not be ruled out, even in the absence of typical clinical symptoms and clear imaging and laboratory examination evidence. Multimodal imaging and immunohistochemical analysis are critical for accurate diagnosis. Early intervention and regular monitoring optimize outcomes and reduce misdiagnosis risks. Regular follow-up is vital to detect disease changes early and adjust treatment plans promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.